Autor: "Bang YJ" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients.
Autorzy:: Bang YJ; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kwon WK; Department of Laboratory and Genetics, Sungkyunkwan University School of Medicine, Seoul, Korea.
Nam SJ; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim SW; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Chae BJ; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee SK; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ryu JM; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kim JW; Department of Laboratory and Genetics, Sungkyunkwan University School of Medicine, Seoul, Korea.
Yu J; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee JE; Division of Breast Surgery, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Pokaż więcej
Źródło:: Cancer research and treatment [Cancer Res Treat] 2022 Jul; Vol. 54 (3), pp. 827-833. Date of Electronic Publication: 2021 Oct 13.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/pathology
Genetic Predisposition to Disease*
Asian People/genetics ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Female ; Genes, BRCA1 ; Genes, BRCA2 ; Humans ; Mutation

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer.
Autorzy:: Müller V; Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany. .
Clemens M; Innere Medizin I, Klinikum Mutterhaus der Borromäerinnen gGmbH, Feldstraße 16, 54290, Trier, Germany.; Current affiliation: CaritasKlinikum Saarbrücken, St. Theresia, Rheinstraße 2, D-66113, Saarbrücken, Germany.
Jassem J; Department of Oncology and Radiotherapy, Medical University of Gdańsk, M. Skłodowskiej-Curie 3a, 80-210, Gdańsk, Poland.
Al-Sakaff N; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Auclair P; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Nüesch E; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Holloway D; F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070, Basel, Switzerland.
Shing M; Genentech, Inc., Global Pharma Development, 1 DNA Way, South San Francisco, CA, 94080, USA.
Bang YJ; Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2018 Mar 15; Vol. 18 (1), pp. 295. Date of Electronic Publication: 2018 Mar 15.
Typ publikacji:: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*metabolism
Breast Neoplasms/*drug therapy
Receptor, ErbB-2/*metabolism
Stomach Neoplasms/*drug therapy
Trastuzumab/*therapeutic use
Adult ; Aged ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Prognosis ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.
Autorzy:: Reynolds KL; Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA. .
Bedard PL; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Lee SH; Seoul National University College of Medicine, Seoul, Republic of Korea.
Lin CC; National Taiwan University Hospital, Taipei, Taiwan.
Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Alsina M; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Cohen E; Moores Cancer Center, University of California at San Diego, La Jolla, CA, USA.
Baselga J; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Blumenschein G Jr; Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Graham DM; Princess Margaret Cancer Centre, Toronto, ON, Canada.
Garrido-Laguna I; Huntsman Cancer Institute, Salt Lake City, UT, USA.
Juric D; Massachusetts General Hospital, 55 Fruit Street, Boston, MA, 02114, USA.
Sharma S; Huntsman Cancer Institute, Salt Lake City, UT, USA.
Salgia R; University of Chicago, Chicago, IL, USA.; City of Hope, Department of Medical Oncology and Therapeutics Research, Duarte, CA, USA.
Seroutou A; Novartis Pharma AG, Basel, Switzerland.
Tian X; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Fernandez R; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Morozov A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.; Pfizer Inc., New York, NY, USA.
Sheng Q; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Ramkumar T; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Zubel A; Novartis Pharma AG, Basel, Switzerland.
Bang YJ; Seoul National University College of Medicine, Seoul, Republic of Korea.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2017 Sep 12; Vol. 17 (1), pp. 646. Date of Electronic Publication: 2017 Sep 12.
Typ publikacji:: Clinical Trial, Phase I; Journal Article
MeSH Terms:: Antineoplastic Agents, Immunological/*administration & dosage
Breast Neoplasms/*drug therapy
Carcinoma, Squamous Cell/*drug therapy
Esophageal Neoplasms/*drug therapy
Head and Neck Neoplasms/*drug therapy
Stomach Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents, Immunological/adverse effects ; Bayes Theorem ; Breast Neoplasms/genetics ; Breast Neoplasms/pathology ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/pathology ; Dose-Response Relationship, Drug ; Esophageal Neoplasms/genetics ; Esophageal Neoplasms/pathology ; Female ; Head and Neck Neoplasms/genetics ; Head and Neck Neoplasms/pathology ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Receptor, ErbB-2/genetics ; Receptor, ErbB-3/genetics ; Squamous Cell Carcinoma of Head and Neck ; Stomach Neoplasms/genetics ; Stomach Neoplasms/pathology